1
|
Milyutin Y, Abud-Hawa M, Kloper-Weidenfeld V, Mansour E, Broza YY, Shani G, Haick H. Fabricating and printing chemiresistors based on monolayer-capped metal nanoparticles. Nat Protoc 2021; 16:2968-2990. [PMID: 34012107 DOI: 10.1038/s41596-021-00528-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 02/23/2021] [Indexed: 02/03/2023]
Abstract
Chemiresistors that are based on monolayer-capped metal nanoparticles (MCNPs) have been used in a wide variety of innovative sensing applications, including detection and monitoring of diagnostic markers in body fluids, explosive materials, environmental contaminations and food quality control. The sensing mechanism is based on reversible swelling or aggregation and/or changes in dielectric constant of the MCNPs. In this protocol, we describe a procedure for producing MCNP-based chemiresistive sensors that is reproducible from device to device and from batch to batch. The approach relies on three main steps: (i) controlled synthesis of gold MCNPs, (ii) fabrication of electrodes that are surrounded with a microbarrier ring to confine the deposited MCNP solution and (iii) a tailor-made drying process to enable evaporation of solvent residues from the MCNP sensing layer to prevent a coffee-ring effect. Application of this approach has been shown to produce devices with ±1.5% variance-a value consistent with the criterion for commercial sensors-as well as long shelf life and stability. Fabrication of chemical sensors based on dodecanethiol- or 2-ethylhexanethiol-capped MCNPs with this approach provides high sensitivity and accuracy in the detection of volatile organic compounds (e.g., octane and decane), toxic gaseous species (e.g., HCl and NH3) in air and simulated mixtures of lung and gastric cancer from exhaled breath.
Collapse
Affiliation(s)
- Yana Milyutin
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel
| | - Manal Abud-Hawa
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel
| | - Viki Kloper-Weidenfeld
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel
| | - Elias Mansour
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel
| | - Yoav Y Broza
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel
| | - Gidi Shani
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel
| | - Hossam Haick
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel.
| |
Collapse
|
2
|
Finberg JPM, Aluf Y, Loboda Y, Nakhleh MK, Jeries R, Abud-Hawa M, Zubedat S, Avital A, Khatib S, Vaya J, Haick H. Altered Volatile Organic Compound Profile in Transgenic Rats Bearing A53T Mutation of Human α-Synuclein: Comparison with Dopaminergic and Serotonergic Denervation. ACS Chem Neurosci 2018; 9:291-297. [PMID: 29017011 DOI: 10.1021/acschemneuro.7b00318] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Early diagnosis of Parkinson's disease (PD) is of great importance due its progressive phenotype. Neuroprotective drugs could potentially slow down disease progression if used at early stages. Previously, we have reported an altered content of volatile organic compounds (VOCs) in the breath of rats following a 50% reduction in striatal dopamine (DA) content induced by 6-hydroxydopamine. We now report on the difference in the breath-print and content of VOCs between rats with mild and severe lesions of DA neurons, serotonergic neuronal lesions, and transgenic (Tg) rats carrying the PD-producing A53T mutation of the SNCA (α-synuclein) gene. The Tg rats had an increased content of 3-octen-1-ol and 4-chloro-3-methyl phenol in blood, while in brain tissue, hexanal, hexanol, and 2,3-octanedione were present in controls but absent in Tg rats. Levels of 1-heptyl-2-methyl cyclopropane were increased in brain tissue of Tg rats. The data confirm the potential of breath analysis for detection of human idiosyncratic as well as autosomal dominant PD.
Collapse
Affiliation(s)
- John P. M. Finberg
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Yuval Aluf
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Yelena Loboda
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Morad K. Nakhleh
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Raneen Jeries
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Manal Abud-Hawa
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Salman Zubedat
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Avi Avital
- Neuroscience Department,
Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Soliman Khatib
- Laboratory of Natural Medicinal Compounds, Migal-Galilee Research
Institute, Kiryat Shmona and Tel Hai College, Qiryat Shemona, 1220800, Israel
| | - Jacob Vaya
- Laboratory of Natural Medicinal Compounds, Migal-Galilee Research
Institute, Kiryat Shmona and Tel Hai College, Qiryat Shemona, 1220800, Israel
| | - Hossam Haick
- Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| |
Collapse
|
3
|
Nardi-Agmon I, Abud-Hawa M, Liran O, Gai-Mor N, Ilouze M, Onn A, Bar J, Shlomi D, Haick H, Peled N. Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer. J Thorac Oncol 2016; 11:827-37. [PMID: 26968885 DOI: 10.1016/j.jtho.2016.02.017] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 02/22/2016] [Accepted: 02/23/2016] [Indexed: 01/28/2023]
Abstract
INTRODUCTION The Response Evaluation Criteria in Solid Tumors (RECIST) serve as the accepted standard to monitor treatment efficacy in lung cancer. However, the time intervals between consecutive computerized tomography scans might be too long to allow early identification of treatment failure. This study examines the use of breath sampling to monitor responses to anticancer treatments in patients with advanced lung cancer. METHODS A total of 143 breath samples were collected from 39 patients with advanced lung cancer. The exhaled breath signature, determined by gas chromatography/mass spectrometry and a nanomaterial-based array of sensors, was correlated with the response to therapy assessed by RECIST: complete response, partial response, stable disease, or progressive disease. RESULTS Gas chromatography/mass spectrometry analysis identified three volatile organic compounds as significantly indicating disease control (PR/stable disease), with one of them also significantly discriminating PR/stable disease from progressive disease. The nanoarray had the ability to monitor changes in tumor response across therapy, also indicating any lack of further response to therapy. When one-sensor analysis was used, 59% of the follow-up samples were identified correctly. There was 85% success in monitoring disease control (stable disease/partial response). CONCLUSION Breath analysis, using mainly the nanoarray, may serve as a surrogate marker for the response to systemic therapy in lung cancer. As a monitoring tool, it can provide the oncologist with a quick bedside method of identifying a lack of response to an anticancer treatment. This may allow quicker recognition than does the current RECIST analysis. Early recognition of treatment failure could improve patient care.
Collapse
Affiliation(s)
- Inbar Nardi-Agmon
- Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel-Aviv, Israel
| | - Manal Abud-Hawa
- Department of Chemical Engineering, Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel
| | - Ori Liran
- Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel-Aviv, Israel
| | - Naomi Gai-Mor
- Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel-Aviv, Israel
| | - Maya Ilouze
- Thoracic Cancer Unit, Davidoff Cancer Center, Rabin Medical Center, Israel
| | - Amir Onn
- Thoracic Oncology Unit, Institute of Oncology, Sheba Medical Center, Tel-Aviv, Israel
| | - Jair Bar
- Thoracic Oncology Unit, Institute of Oncology, Sheba Medical Center, Tel-Aviv, Israel
| | - Dekel Shlomi
- Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel-Aviv, Israel
| | - Hossam Haick
- Thoracic Oncology Unit, Institute of Oncology, Sheba Medical Center, Tel-Aviv, Israel.
| | - Nir Peled
- Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel-Aviv, Israel; Thoracic Cancer Unit, Davidoff Cancer Center, Rabin Medical Center, Israel
| |
Collapse
|
4
|
Peled N, Abud-Hawa M, Liran O, Ilouze M, Gai-Mor N, Shlomi D, Ben-Nun A, Onn A, Bar J, Johnson D, Wells J, Millstone S, Bunn PA, Miller YE, Keith RL, Rikke B, Hirsch FR, Haick H. Breath analysis as a noninvasive biomarker for early detection of lung cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.7560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Nir Peled
- Thoracic Cancer Unit, Davidoff Cancer Center, Rabin Medical Center, Petach Tikwa, Israel
| | - Manal Abud-Hawa
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion, Israel Institute of Technology, Haifa, Israel
| | - Ori Liran
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Maya Ilouze
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Naomi Gai-Mor
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Dekel Shlomi
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Alon Ben-Nun
- Thoracic Oncology Unit, Institute of Oncology, Sheba Medical Center, Ramat-Gan, Israel
| | - Amir Onn
- Institute of Oncology, Chaim Sheba Medical Center, Ramat-Gan, Israel
| | - Jair Bar
- Thoracic Oncology Unit, Institute of Oncology, Sheba Medical Center, Ramat-Gan, Israel
| | | | - John Wells
- Florida Radiation Oncology Group, Jacksonville, FL
| | | | - Paul A. Bunn
- University of Colorado Cancer Center, Aurora, CO
| | | | | | - Brad Rikke
- University of Colorado Cancer Center, Denver, CO
| | | | - Hossam Haick
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion, Israel Institute of Technology, Haifa, Israel
| |
Collapse
|
5
|
Nardi-Agmon I, Abud-Hawa M, Liran O, Gai-Mor N, Ilouze M, Onn A, Bar J, Navon R, Hirsch FR, Bunn PA, Haick H, Peled N. RECIST measurement through the exhaled breath in lung cancer: Myth or reality? J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e19023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Inbar Nardi-Agmon
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Manal Abud-Hawa
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion, Israel Institute of Technology, Haifa, Israel
| | - Ori Liran
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Naomi Gai-Mor
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Maya Ilouze
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Amir Onn
- Institute of Oncology, Chaim Sheba Medical Center, Ramat-Gan, Israel
| | - Jair Bar
- Thoracic Oncology Unit, Institute of Oncology, Sheba Medical Center, Ramat-Gan, Israel
| | - Rossie Navon
- Thoracic Oncology Unit, Institute of Oncology, Sheba Medical Center, Ramat-Gan, Israel
| | | | - Paul A. Bunn
- University of Colorado Cancer Center, Aurora, CO
| | - Hossam Haick
- Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion, Israel Institute of Technology, Haifa, Israel
| | - Nir Peled
- The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan, Israel
| |
Collapse
|